Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...